Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration Enrollment of over 150 participants anticipated in Belgium Lyon, France – November 14, 2024 – Osivax, a biopharmaceutical …
Archives de la catégorie : 2024
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine candidates in Japan Osivax is to receive upfront payment for execution …
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033 48 healthy volunteers enrolled in first-in-human trial Topline data read-out expected by Q4 2024 Lyon, France – June 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has completed …
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs 478 participants were enrolled across Australia Full immunogenicity and safety results expected in the second half of 2024 Lyon, France – March 26, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that …
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels The trial will enroll 48 participants in France Lyon, France – February 15, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer Lyon, France – January 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience …
Continuer la lecture « Osivax Appoints Dr. Nicola Groth as Chief Medical Officer »